特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肺移植拒絶反応:パイプライン製品の分析

Lung Transplant Rejection - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 395245
出版日 ページ情報 英文 89 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
肺移植拒絶反応:パイプライン製品の分析 Lung Transplant Rejection - Pipeline Review, H1 2020
出版日: 2020年05月30日 ページ情報: 英文 89 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

肺移植は、肺の様々な疾患において使用される治療法です。肺移植とは、損傷したり罹患した肺を健康なものと取り替える手術です。肺移植に関連したリスク要因として、出血、感染症、血栓、循環器疾患などがあります。移植後、免疫システムが移植された肺を異物とみなして攻撃することがあります。そのため、患者は合併症を発症し、最終的には新しい臓器を拒絶してしまいます。免疫抑制薬を同時に投与し、体が様々な免疫反応によって外部から来た臓器を同定あるいは攻撃するのを防ぎます。それによって臓器の拒絶反応を遮断し、移植の成功を促します。

当レポートでは、肺移植拒絶反応に関連する薬剤の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

肺移植拒絶反応の概要

治療薬の開発

  • パイプライン製品の概要
  • 企業別のパイプライン
  • 企業で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Dompe Farmaceutici SpA
  • Kamada Ltd
  • Novartis AG
  • Quark Pharmaceuticals Inc

薬剤プロファイル

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Lung Transplant Rejection, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Lung Transplant Rejection - Pipeline by Amgen Inc, H1 2020
  • Lung Transplant Rejection - Pipeline by Apeptico Forschung und Entwicklung GmbH, H1 2020
  • Lung Transplant Rejection - Pipeline by Astellas Pharma Inc, H1 2020
  • Lung Transplant Rejection - Pipeline by Exscien Corp, H1 2020
  • Lung Transplant Rejection - Pipeline by Kamada Ltd, H1 2020
  • Lung Transplant Rejection - Pipeline by MimeTech Srl, H1 2020
  • Lung Transplant Rejection - Pipeline by Proteo Inc, H1 2020
  • Lung Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc, H1 2020
  • Lung Transplant Rejection - Pipeline by Radikal Therapeutics Inc, H1 2020
  • Lung Transplant Rejection - Pipeline by Sangamo Therapeutics Inc, H1 2020
  • Lung Transplant Rejection - Pipeline by TFF Pharmaceuticals Inc, H1 2020
  • Lung Transplant Rejection - Pipeline by Theravance Biopharma Inc, H1 2020
  • Lung Transplant Rejection - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Lung Transplant Rejection, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC12211IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lung Transplant Rejection - Pipeline Review, H1 2020, provides an overview of the Lung Transplant Rejection (Immunology) pipeline landscape.

Lung transplantation is the therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lung Transplant Rejection - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Lung Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lung Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 3 and 10 respectively.

Lung Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Lung Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lung Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lung Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Lung Transplant Rejection (Immunology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lung Transplant Rejection (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lung Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lung Transplant Rejection - Overview
    • Lung Transplant Rejection - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Lung Transplant Rejection - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Lung Transplant Rejection - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Apeptico Forschung und Entwicklung GmbH
    • Astellas Pharma Inc
    • Exscien Corp
    • Kamada Ltd
    • MimeTech Srl
    • Proteo Inc
    • Quark Pharmaceuticals Inc
    • Radikal Therapeutics Inc
    • Sangamo Therapeutics Inc
    • TFF Pharmaceuticals Inc
    • Theravance Biopharma Inc
  • Lung Transplant Rejection - Drug Profiles
    • alpha-1 proteinase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • carfilzomib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Exscien-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • QPLI-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-554 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • solnatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tacrolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tacrolimus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TD-0903 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tiprelestat - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TX-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • udonitrectag - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Lung Transplant Rejection - Dormant Projects
  • Lung Transplant Rejection - Product Development Milestones
    • Featured News & Press Releases
      • Oct 18, 2019: New insights into Alpha-1 Deficiency: A special scientific meeting organized by Kamada during the recent ERS congress
      • Feb 06, 2019: Kamada announces additional interim results from phase 2 proof of concept clinical trial of intravenous Alpha-1 Antitrypsin treatment for prevention of Lung Transplant Rejection
      • Jan 08, 2018: Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
      • Jun 19, 2017: TxCell Appoints Lentigen Technology To Manufacture the Lentiviral Vector for Its First CAR-Treg Program in Transplant Rejection
      • Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
      • Dec 09, 2015: Quark announces issue of U.S. patent for novel treatment of lung transplantation associated injury
      • Oct 05, 2015: APEPTICO receives Orphan Drug Designation by European Medicines Agency
      • Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
      • Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs
      • Mar 03, 2015: APEPTICO provides update on phase Iia study of AP301 product candidate
      • Jul 08, 2013: APEPTICO receives research grant from Austrian Research Promotion Agency (FFG)
      • Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation
      • Jan 31, 2013: APEPTICO announces publication of article in the journal Pulmonary Pharmacology and Therapeutics
      • Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program
      • Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer